Trial Profile
Randomised study of rituximab (IDEC C2B8) in patients with relapsed follicular lymphoma prior to high dose therapy as in vivo purging and to maintain remission following high dose therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Oct 2005
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 27 Oct 2005 New trial record.